AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License

Rhea-AI Summary

AIkido Pharma Inc. (Nasdaq: AIKI) announced funding for a 30-day survival study in mice at the University of Kentucky, related to the anticancer drug G4-1, a novel proteasome inhibitor. In exchange for the funding, AIkido receives an exclusive option to license the drug, contingent on study results. The Option includes two patents expiring in the mid-2030s. CEO Anthony Hayes highlighted promising preliminary data for G4-1 compared to existing drugs, anticipating positive study results to enhance their oncology portfolio.

Positive

• Funding a survival study for G4-1, indicating commitment to research and development.
• Exclusive option to license G4-1, potentially expanding product offerings.
• Promising preliminary data showing G4-1's effectiveness against solid tumors.

Negative

• None.

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido has been granted an exclusive option to license the drug ("Option") pending the results of the study. 

The Option includes two issued patents, United States Patent Nos. 9,493,439 and 9,586,946, each having expiration dates in the mid-2030's. AIkido was previously granted an option to license these patents, which it did not exercise in favor of performing this further research.

Mr. Anthony Hayes, CEO of AIkido stated, "The published mouse data on G4-1 shows exciting promise for the treatment of solid tumors compared to already approved drugs. Given those encouraging preliminary results, we agreed to fund a survival study to determine whether G4-1 can also increase survival over the marketed drugs. This transaction represents another low-risk initiative to bolster our portfolio. We optimistically anticipate the results of this study and hope they support adding G4-1 to our oncology products." 

Dr. Chang-Guo Zhan, Professor, College of Pharmacy at the University of Kentucky, added, "Proteasome inhibitors in current clinical use are all peptides with very low in vivo stability. G4–1 is a non-peptide proteasome inhibitor with the desirably high in vivo stability required for the treatment of solid tumors. We are excited about the opportunity to further evaluate the therapeutic potential of G4-1 with funding supporting from AIkido."

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations:	Hayden IR
	Brett Maas, Managing Partner
	Phone: (646) 536-7331
	Email: brett@haydenir.com
	www.haydenir.com
AIkido:	Phone: 212-745-1373
	Email: investorrelations@AIkido.com
	www.AIkido.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-sponsors-survival-study-of-university-of-kentucky-anticancer-drug-g4-1-in-exchange-for-exclusive-option-to-license-301113847.html

SOURCE AIkido Pharma Inc.

FAQ

What study is AIkido Pharma sponsoring related to G4-1?

AIkido Pharma is sponsoring a 30-day survival study in mice at the University of Kentucky to evaluate the anticancer drug G4-1.

What is the significance of the exclusive option granted to AIkido Pharma?

The exclusive option allows AIkido to license the G4-1 drug pending favorable results from the survival study.

When was the press release regarding G4-1 published?

The press release was published on August 18, 2020.

What patents are included in the licensing option for G4-1?

The option includes United States Patent Nos. 9,493,439 and 9,586,946, both expiring in the mid-2030s.

What are G4-1's potential advantages compared to existing drugs?

G4-1 is a non-peptide proteasome inhibitor with high in vivo stability, showing promise for treating solid tumors more effectively than current peptide-based drugs.